Watch Ticker

Genmab A/S ADS

Go to Genmab A/S ADS Website

$22.01

0.03 (0.14%)

Live

Previous Close

$21.98

Day Range

$0 - $0

Previous Day Range

$21.69 - $22.06

Market Cap

$13.4 billion USD

Day Vol.

Previous Day Vol.

967090

Currency

USD

Primary Exchange

Nasdaq

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Genmab A/S - Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

Genmab's investigational epcoritamab combination therapy showed high response rates in patients with relapsed or refractory DLBCL eligible for ASCT, with an ORR of 87% and a CR rate of 65%. The combination therapy demonstrated the potential to increase the proportion of patients who qualify for ASCT.

Related tickers: GMAB.

Read Full Article

Genmab A/S - Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

Genmab's investigational drug Rina-S showed promising anti-tumor activity in a Phase 1/2 trial for advanced endometrial cancer patients, with a 50% confirmed objective response rate and two complete responses.

Related tickers: GMAB.

Read Full Article

Trending Tickers

Please sign in to view